The Heart Protection Study: expanding the boundaries for high-risk coronary disease prevention (Q35179555)

7 August 2017

1 reference

title

The Heart Protection Study: expanding the boundaries for high-risk coronary disease prevention (English)

1 reference

7 August 2017

John A Farmer

1

1 reference

PubMed ID

12867249

7 August 2017

Antonio M Gotto

series ordinal

2

1 reference

PubMed ID

12867249

7 August 2017

language of work or name

English

0 references

publication date

1 July 2003

1 reference

American Journal of Cardiology

7 August 2017

1 reference

7 August 2017

92

1 reference

7 August 2017

1A

1 reference

7 August 2017

3i-9i

1 reference

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

7 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900503-4

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900503-4

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900503-4

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900503-4

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900503-4

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900503-4

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900503-4

Representation of elderly persons and women in published randomized trials of acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900503-4

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900503-4

MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900503-4

Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900503-4

Antiatherosclerotic effects of antioxidants are lesion-specific when evaluated in hypercholesterolemic New Zealand white rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900503-4

Intake of vegetables rich in carotenoids and risk of coronary heart disease in men: The Physicians' Health Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900503-4

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900503-4

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900503-4

Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900503-4

MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900503-4

Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900503-4

Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900503-4

Current status of risk factors for stroke

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900503-4

Lipoproteins, cardiovascular disease, and death. The Framingham study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900503-4

Risk of hospitalized stroke in men enrolled in the Honolulu Heart Program and the Framingham Study: A comparison of incidence and risk factor effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900503-4

Statin therapy and stroke prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900503-4

Ischemic heart disease risk factors after age 50.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900503-4

Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900503-4

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900503-4

Age and the burden of death attributable to diabetes in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900503-4

Cardiovascular disease in women: a statement for healthcare professionals from the American Heart Association. Writing Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900503-4

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900503-4

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900503-4

Effects of estrogen replacement on the progression of coronary-artery atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900503-4

A clinical trial of estrogen-replacement therapy after ischemic stroke

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900503-4

Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900503-4

Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900503-4

10.1016/S0002-9149(03)00503-4

7 January 2021

Identifiers

DOI

1 reference

7 August 2017

1 reference

PubMed ID

12867249